Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Masitinib mesylate application for conditional approval
SJL mice exposed to cuprizone intoxication reveal strain and gender pattern differences in demyelination.
Cost Effectiveness of Fingolimod, Teriflunomide, Dimethyl Fumarate and Intramuscular Interferon-β1a in Relapsing-Remitting Multiple Sclerosis.
De- and remyelination in the CNS white and grey matter induced by cuprizone: the old, the new, and the unexpected.
Episode 18 with Dr. Samuel Ludwin on new approaches to remyelination therapies.
Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial.
Comparative effectiveness of fingolimod versus interferons or glatiramer acetate for relapse rates in multiple sclerosis: a retrospective US claims database analysis.
Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis.
Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States.
Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study.
Status spongiosus of CNS and hepatic changes induced by cuprizone (biscyclohexanone oxalyldihydrazone).
Episode 20 with Dr. Jeffrey Cohen discussing two MS-related clinical trials
Keystone Symposium: Dendritic Cells and Macrophages Reunited
Request for Applications for Collaborative Network Awards from the Progressive MS Alliance
Episode 7 with Dr. Daniel Kantor on access to care
Spectrophotometric Determination of Serum Copper with Biscyclohexanoneoxalyldihydrazone
Episode 10 with Dr. Richard Ransohoff on his group's latest research
ForuMS: A Virtual Journal Club for MS Clinicians
Neuroprotection in a novel mouse model of multiple sclerosis.
Environmental factors in multiple sclerosis: Epstein-Barr virus, vitamin D, and cigarette smoking.
17beta-estradiol and progesterone prevent cuprizone provoked demyelination of corpus callosum in male mice.
The role of natural killer cells in multiple sclerosis and their therapeutic implications.
Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination.
46th Annual WCBR Winter Conference on Brain Research
The force awakens: insights into the origin and formation of microglia.
Pages
« first
‹ previous
…
54
55
56
57
58
59
60
61
62
…
next ›
last »